Grace M Lee1, Ken Kleinman2, Stephen I Pelton3, William Hanage4, Susan S Huang5, Matthew Lakoma2, Maya Dutta-Linn2, Nicholas J Croucher4, Abbie Stevenson4, Jonathan A Finkelstein6. 1. Center for Child Health Care Studies, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School Division of Infectious Diseases and Department of Laboratory Medicine, Boston Children's Hospital. 2. Center for Child Health Care Studies, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School. 3. Department of Pediatrics, Boston University School of Medicine. 4. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts. 5. Division of Infectious Diseases, University of California Irvine. 6. Center for Child Health Care Studies, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School Department of Medicine, Boston Children's Hospital, Massachusetts.
Abstract
BACKGROUND: In April 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 for use in the United States. We evaluated rates of pneumococcal colonization, by serotype and antibiotic resistance, in Massachusetts communities where serial cross-sectional surveillance has been conducted for the past decade. METHODS: Nasopharyngeal swabs were obtained from children 0 to <7 years of age and seen by primary care providers for well child or acute illness visits in 2001, 2004, 2007, 2009, and 2011. Pneumococcal isolates were serotyped by Quellung reaction and classified as PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F), additional PCV13 serotypes (1, 3, 5, 6A, 7F, 19A), or non-PCV13 serotypes. Changes in colonization and impact of PCV13 were assessed using generalized linear mixed models, adjusting for known risk factors and accounting for clustering by community. RESULTS: Introduction of PCV13 did not affect the rate of overall pneumococcal colonization (31% in 2011). Colonization with non-PCV13 serotypes increased between 2001 and 2011 for all children (odds ratio [OR] per year, 1.12; 95% confidence interval [CI], 1.10, 1.15; P < .0001). 19A remained the second most common serotype in 2011, although a decline from 2009 was observed. Penicillin (7%), erythromycin (28%), ceftriaxone (10%), and clindamycin (10%) nonsusceptibility were commonly identified, concentrated among a small number of serotypes (including 19A, 35B, 15B/C, and 15A). Among healthy children 6-23 months old, colonization with PCV13 serotypes was lower among recipients of PCV13 vaccine (adjusted OR, 0.30; 95% CI, 0.11, 0.78). This effect was not observed in 6- to 23-month-old children with a concomitant respiratory tract infection (adjusted OR 1.36; 95% CI, 0.66, 2.77) or children 2 to <7 years old (adjusted OR, 1.17; 95% CI, 0.58, 2.34). CONCLUSIONS: 13-Valent pneumococcal conjugate vaccine reduced the prevalence of colonization with PCV13 serotypes among children 6-23 months old, but its efficacy was not shown among older children.
BACKGROUND: In April 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 for use in the United States. We evaluated rates of pneumococcal colonization, by serotype and antibiotic resistance, in Massachusetts communities where serial cross-sectional surveillance has been conducted for the past decade. METHODS: Nasopharyngeal swabs were obtained from children 0 to <7 years of age and seen by primary care providers for well child or acute illness visits in 2001, 2004, 2007, 2009, and 2011. Pneumococcal isolates were serotyped by Quellung reaction and classified as PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F), additional PCV13 serotypes (1, 3, 5, 6A, 7F, 19A), or non-PCV13 serotypes. Changes in colonization and impact of PCV13 were assessed using generalized linear mixed models, adjusting for known risk factors and accounting for clustering by community. RESULTS: Introduction of PCV13 did not affect the rate of overall pneumococcal colonization (31% in 2011). Colonization with non-PCV13 serotypes increased between 2001 and 2011 for all children (odds ratio [OR] per year, 1.12; 95% confidence interval [CI], 1.10, 1.15; P < .0001). 19A remained the second most common serotype in 2011, although a decline from 2009 was observed. Penicillin (7%), erythromycin (28%), ceftriaxone (10%), and clindamycin (10%) nonsusceptibility were commonly identified, concentrated among a small number of serotypes (including 19A, 35B, 15B/C, and 15A). Among healthy children 6-23 months old, colonization with PCV13 serotypes was lower among recipients of PCV13 vaccine (adjusted OR, 0.30; 95% CI, 0.11, 0.78). This effect was not observed in 6- to 23-month-old children with a concomitant respiratory tract infection (adjusted OR 1.36; 95% CI, 0.66, 2.77) or children 2 to <7 years old (adjusted OR, 1.17; 95% CI, 0.58, 2.34). CONCLUSIONS: 13-Valent pneumococcal conjugate vaccine reduced the prevalence of colonization with PCV13 serotypes among children 6-23 months old, but its efficacy was not shown among older children.
Authors: Susan S Huang; Virginia L Hinrichsen; Abbie E Stevenson; Sheryl L Rifas-Shiman; Ken Kleinman; Stephen I Pelton; Marc Lipsitch; William P Hanage; Grace M Lee; Jonathan A Finkelstein Journal: Pediatrics Date: 2009-07 Impact factor: 7.124
Authors: Robert Weatherholtz; Eugene V Millar; Lawrence H Moulton; Raymond Reid; Karen Rudolph; Mathuram Santosham; Katherine L O'Brien Journal: Clin Infect Dis Date: 2010-05-01 Impact factor: 9.079
Authors: Laura L Hammitt; Dana L Bruden; Jay C Butler; Henry C Baggett; Debby A Hurlburt; Alisa Reasonover; Thomas W Hennessy Journal: J Infect Dis Date: 2006-04-27 Impact factor: 5.226
Authors: Katherine L O'Brien; Eugene V Millar; Elizabeth R Zell; Melinda Bronsdon; Robert Weatherholtz; Raymond Reid; Jocelyn Becenti; Sheri Kvamme; Cynthia G Whitney; Mathuram Santosham Journal: J Infect Dis Date: 2007-09-17 Impact factor: 5.226
Authors: Stephen I Pelton; Heather Huot; Jonathan A Finkelstein; C J Bishop; Katherine K Hsu; Joan Kellenberg; Susan S Huang; Richard Goldstein; William P Hanage Journal: Pediatr Infect Dis J Date: 2007-06 Impact factor: 2.129
Authors: Lindsay R Grant; Laura L Hammitt; Sarah E O'Brien; Michael R Jacobs; Connie Donaldson; Robert C Weatherholtz; Raymond Reid; Mathuram Santosham; Katherine L O'Brien Journal: Pediatr Infect Dis J Date: 2016-08 Impact factor: 2.129
Authors: Michelle McFarland; Taylor P Szasz; Julie Y Zhou; Kara Motley; Janardan S Sivapalan; Megan Isaacson-Schmid; Elizabeth M Todd; Patrick G Hogan; Stephanie A Fritz; Carey-Ann D Burnham; Steen Hoffmann; Sharon Celeste Morley Journal: Vaccine Date: 2017-07-04 Impact factor: 3.641
Authors: Grace M Lee; Ken Kleinman; Stephen Pelton; Marc Lipsitch; Susan S Huang; Matt Lakoma; Maya Dutta-Linn; Melisa Rett; William P Hanage; Jonathan A Finkelstein Journal: Pediatrics Date: 2017-10-04 Impact factor: 7.124